BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines 2015;14:749-62. [PMID: 25597843 DOI: 10.1586/14760584.2015.1001750] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Faith MR, Juliet B, Tumuhamye N, Mathias T, Sacks E. Factors associated with the utilization of inactivated polio vaccine among children aged 12 to 23 months in Kalungu District, Uganda. Health Policy Plan 2020;35:i30-7. [PMID: 33165582 DOI: 10.1093/heapol/czaa099] [Reference Citation Analysis]
2 Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis. Hum Vaccin Immunother 2018;14:2636-43. [PMID: 29985751 DOI: 10.1080/21645515.2018.1489188] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, Yang J, Yin Z, Wang J, Chu J, Cai W, Zhou J, Wang J, Li Q. Phase 3 Trial of a Sabin Strain–Based Inactivated Poliovirus Vaccine. J Infect Dis 2016;214:1728-34. [DOI: 10.1093/infdis/jiw433] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
4 Duyvesteyn HME, Ren J, Walter TS, Fry EE, Stuart DI. Glutathione facilitates enterovirus assembly by binding at a druggable pocket. Commun Biol 2020;3:9. [PMID: 31909201 DOI: 10.1038/s42003-019-0722-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Nomhwange TI, Shuaib F, Braka F, Godwin S, Kariko U, Gregory U, Tegegne SG, Okposen B, Onoka C. Routine immunization community surveys as a tool for guiding program implementation in Kaduna state, Nigeria 2015-2016. BMC Public Health 2018;18:1313. [PMID: 30541515 DOI: 10.1186/s12889-018-6197-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Trogdon JG, Shafer P, Lindsay B, Coyne-Beasley T. Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina. Vaccine 2018;36:1310-5. [PMID: 29366705 DOI: 10.1016/j.vaccine.2018.01.014] [Reference Citation Analysis]
7 Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines 2016;15:693-708. [PMID: 26751187 DOI: 10.1586/14760584.2016.1140041] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
8 Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology 2016;11:1549-61. [DOI: 10.2217/fmb-2016-0126] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
9 Chong WC, Chellappan DK, Shukla SD, Peterson GM, Patel RP, Jha NK, Eri RD, Dua K, Tambuwala MM, Shastri MD. An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses 2021;13:1397. [PMID: 34372603 DOI: 10.3390/v13071397] [Reference Citation Analysis]
10 Jiang B, Patel M, Glass RI. Polio endgame: Lessons for the global rotavirus vaccination program. Vaccine 2019;37:3040-9. [DOI: 10.1016/j.vaccine.2019.04.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing vaccine safety capacity globally: A lifecycle perspective. Vaccine 2015;33 Suppl 4:D46-54. [PMID: 26433922 DOI: 10.1016/j.vaccine.2015.06.073] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
12 Tesfaye B, Sowe A, Kisangau N, Ogange J, Ntoburi S, Nekar I, Muitherero C, Camara Y, Gathenji C, Langat D, Sergon K, Limo H, Nzunza R, Kiptoon S, Kareko D, Onuekwusi I. An epidemiological analysis of Acute Flaccid Paralysis (AFP) surveillance in Kenya, 2016 to 2018. BMC Infect Dis 2020;20:611. [PMID: 32811467 DOI: 10.1186/s12879-020-05319-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
14 Ramirez Gonzalez A, Farrell M, Menning L, Garon J, Everts H, Hampton LM, Dolan SB, Shendale S, Wanyoike S, Veira CL, Châtellier GMD, Kurji F, Rubin J, Boualam L, Chang Blanc D, Patel M. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective. J Infect Dis 2017;216:S183-92. [PMID: 28838179 DOI: 10.1093/infdis/jiw626] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
15 Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, Shi X, Guo Y, Sun Y, Li H, Li N, Han S, Ma M, Yang X. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. Vaccine 2020;38:6274-9. [PMID: 32747216 DOI: 10.1016/j.vaccine.2020.07.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Abba B, Abdullahi S, Bawa S, Getso KI, Bello IW, Korir C, Musa A, Braka F, Ningi A, Nsubuga P, Banda R, Tegegne SG, Shuaib F, Adamu US, Haladu S. Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016. BMC Public Health 2018;18:1302. [PMID: 30541496 DOI: 10.1186/s12889-018-6195-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Kraan H, van der Stel W, Kersten G, Amorij J. Alternative administration routes and delivery technologies for polio vaccines. Expert Review of Vaccines 2016;15:1029-40. [DOI: 10.1586/14760584.2016.1158650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Zhang Z, Dong Z, Wang Q, Carr MJ, Li J, Liu T, Li D, Shi W. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine 2018;36:7095-104. [PMID: 30316529 DOI: 10.1016/j.vaccine.2018.09.069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Patel M, Cochi S. Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future. J Infect Dis 2017;216:S1-8. [PMID: 28838196 DOI: 10.1093/infdis/jix117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
20 Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, Pallansch MA, Oberste MS, Villinger F, Orenstein W, Murali-Krishna K. Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses. Clin Infect Dis 2018;67:S66-77. [PMID: 30376091 DOI: 10.1093/cid/ciy634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Zhao T, Li J, Fu Y, Ye H, Liu X, Li G, Yang X, Yang J. Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine. NPJ Vaccines 2020;5:47. [PMID: 32566258 DOI: 10.1038/s41541-020-0194-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, Yin W. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial. J Infect Dis 2019;220:1551-7. [PMID: 30958543 DOI: 10.1093/infdis/jiy736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
23 Lin LC, Chattopadhyay S, Lin J, Hu CJ. Advances and Opportunities in Nanoparticle- and Nanomaterial-Based Vaccines against Bacterial Infections. Adv Healthcare Mater 2018;7:1701395. [DOI: 10.1002/adhm.201701395] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
24 Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, Wang W, Wang H, Guo S, Li C, Wei S, Mo Z, Xia J. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. Hum Vaccin Immunother 2017;13:1-10. [PMID: 28362135 DOI: 10.1080/21645515.2017.1288769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
25 Agrawal A, Kolhapure S, Di Pasquale A, Rai J, Mathur A. Vaccine Hesitancy as a Challenge or Vaccine Confidence as an Opportunity for Childhood Immunisation in India. Infect Dis Ther 2020;9:421-32. [PMID: 32447713 DOI: 10.1007/s40121-020-00302-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
26 Cimica V, Galarza JM. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin Immunol. 2017;183:99-108. [PMID: 28780375 DOI: 10.1016/j.clim.2017.08.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
27 Trogdon JG, Shafer P, Lindsay B, Coyne-Beasley T. Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina. Vaccine 2018;36:1304-9. [PMID: 29395530 DOI: 10.1016/j.vaccine.2018.01.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Ford-siltz LA, Wales S, Tohma K, Gao Y, Parra GI. Genotype-Specific Neutralization of Norovirus Is Mediated by Antibodies Against the Protruding Domain of the Major Capsid Protein. The Journal of Infectious Diseases 2020. [DOI: 10.1093/infdis/jiaa116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
29 Chen S, Zhao Y, Yang Z, Li Y, Shi H, Zhao T, Yang X, Li J, Li G, Wang J, Ying Z, Yang J. The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy. Hum Vaccin Immunother 2022;:1-6. [PMID: 35044877 DOI: 10.1080/21645515.2021.2024063] [Reference Citation Analysis]
30 Bedada SY, Gallagher K, Aregay AK, Mohammed B, Maalin MA, Hassen HA, Ali YM, Braka F, Kilebou PM. Assessment of source of information for polio supplementary immunization activities in 2014 and 2015, Somali, Ethiopia. Pan Afr Med J 2017;27:7. [PMID: 28983395 DOI: 10.11604/pamj.supp.2017.27.2.10728] [Reference Citation Analysis]
31 Tobin GJ, Tobin JK, Gaidamakova EK, Wiggins TJ, Bushnell RV, Lee WM, Matrosova VY, Dollery SJ, Meeks HN, Kouiavskaia D, Chumakov K, Daly MJ. A novel gamma radiation-inactivated sabin-based polio vaccine. PLoS One 2020;15:e0228006. [PMID: 31999745 DOI: 10.1371/journal.pone.0228006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
32 Ba-Nguz A, Adjagba A, Wisnu Hendrarto T, Sewankambo NK, Nalwadda C, Kisakye A. The Role of National Immunization Technical Advisory Groups (NITAGs) in the Introduction of Inactivated Polio Vaccine: Experience of the Indonesia and Uganda NITAGs. J Infect Dis 2017;216:S109-13. [PMID: 28838176 DOI: 10.1093/infdis/jiw601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
33 Ahn TK, Kang S, Paik JH, Seo YH. Adverse events and preventive measures related to COVID-19 vaccines. Clin Exp Emerg Med 2021;8:153-9. [PMID: 34649403 DOI: 10.15441/ceem.21.067] [Reference Citation Analysis]
34 Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, Ye H, Zhao Z, Liu X, Li J, Li Y, Li R, Jiang R, Wang J, Fu Y, Ma R, Shi H, Yang H, Li C, Yang J, Li Q. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med 2021;9:253. [PMID: 33708880 DOI: 10.21037/atm-20-2537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Garon JR, Orenstein WA. A worldwide shift in polio vaccines for routine immunisation. Lancet 2015;386:2375-7. [PMID: 26388533 DOI: 10.1016/S0140-6736(15)00243-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Garon JR, Cochi SL, Orenstein WA. The Challenge of Global Poliomyelitis Eradication. Infect Dis Clin North Am 2015;29:651-65. [PMID: 26610419 DOI: 10.1016/j.idc.2015.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
37 Cimica V, Galarza JM, Rashid S, Stedman TT. Current development of Zika virus vaccines with special emphasis on virus-like particle technology. Expert Rev Vaccines 2021;:1-16. [PMID: 34148481 DOI: 10.1080/14760584.2021.1945447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Connor RI, Brickley EB, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin JF, Bandyopadhyay AS, Wright PF. Mucosal immunity to poliovirus. Mucosal Immunol 2021. [PMID: 34239028 DOI: 10.1038/s41385-021-00428-0] [Reference Citation Analysis]
39 Nwogu C, Musyoka J, Gathenji C, Nzunza R, Onuekwusi I, Okeibunor J, Mkanda P, Shukla H, Kabir SH, Okiror SO. Overview of Polio Outbreak Response in Kenya, 2013 to 2015. J Immunol Sci 2021;Spec Issue:1103. [PMID: 33954301 DOI: 10.29245/2578-3009/2021/S2.1103] [Reference Citation Analysis]
40 Manyanga D, Masvikeni B, Daniel F. The experiences of using polio outbreak simulation exercises to strengthen national outbreaks preparedness and response plans in sub-Saharan Africa. Pan Afr Med J 2020;36:340. [PMID: 33193993 DOI: 10.11604/pamj.2020.36.340.23824] [Reference Citation Analysis]
41 Garon J, Patel M. The polio endgame: rationale behind the change in immunisation. Arch Dis Child 2017;102:362-5. [PMID: 28096107 DOI: 10.1136/archdischild-2016-311171] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective. Am J Prev Med 2015;49:S364-76. [PMID: 26590436 DOI: 10.1016/j.amepre.2015.09.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]